Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Open accessThe DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.
Abstract
Unprecedented successes regarding cancer immunotherapy have been achieved, in which therapeutic agents are used to target immune cells rather than cancer cells. The most effective immunotherapy to date is the group of immune checkpoint inhibitors (CPI), targeting, for example, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein (PD-1). TThe combination of these therapies (anti-PD-1 with anti-CTLA-4) induces high response rates, and seem to be increased further when applied in early-stage disease. However, combined CTLA-4 plus PD-1 blockade causes frequent high-grade immune-related adverse events (irAE). To date, research on biological mechanism of irAEs is scarce and no widely accepted biomarkers predicting onset of severe irAEs have been identified. The similarity of irAEs to autoimmune disorders fuels the hypothesis that irAEs may be linked to susceptible genetic loci related to various autoimmune diseases. In this review, we extensively searched for susceptible loci associated with various autoimmune diseases, and pooled them in groups most likely to be associated with CPI-induced irAEs. These sets could be used in future research on predicting irAEs and guide physicians in a more refined and personal manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While genetic determinants for autoimmune disease are numerous (Hoefsmit et al., 2019), genetic pre-disposition to irAEs is less well-defined.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hoefsmit et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 2×
“Severe adverse events (AE) from CPI are observed in about 15% of patients treated with anti-PD-1/PD-L1, 20%–30% with ipilimumab and in up to 60% in ipilimumab/nivolumab combination therapy in late-stage disease.(4) 11–17 These AEs, called immune-related (ir)AEs or AEs of special interest, closely resemble autoimmune d…”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Research works printed but not linked: 1
- Petukhova L, Duvic M, Hordinsky M, et al Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466: 113– 7. 10.1038/nature09114 20596022 PMC2921172 · DOI · Paper page
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Classical Examples of the Concept of the ASIA Syndrome
Borba, V. V., Malkova, A. M., Basantsova, N. Y., Halpert, G., Andréoli, L., Tincani, A., Amital, H., & Shoenfeld, Y. (2020) · Biomolecules · doi:10.3390/biom10101436 · Cited by 116
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 121
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 111
“Additionally, thanks to the “Immunochip project”, relevant loci have been identified in genes involved in the T-cell receptor signaling pathway as susceptibility factors for the development of thyroiditis and endocrinopathies [95].”
BackgroundTsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 87
“Due to a substantial number of irAE patients, most relevant knowledge on irAEs comes from human clinical research, which suggests the involvement of dysregulated immune tolerance against autoantigens (11, 12), pathogenic B-cell activation and subsequent autoAb production (12, 13), and T-cell reactivity preferentially…”
BackgroundImmune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 74
A novel mouse model for checkpoint inhibitor-induced adverse events
Adam, K., Iuga, A., Tocheva, A. S., & Mor, A. (2021) · PLOS ONE · doi:10.1371/journal.pone.0246168 · Cited by 64
Gao, L., Yang, X., Cheng, Y., & Zhu, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01173 · Cited by 58
“Interventions for local advanced or metastatic solid tumors have evolved rapidly in recent years, among which immune checkpoint blockade therapy may be the most notable strategy (Pardoll, 2012; Hoos, 2016; Papaioannou et al., 2016).”
BackgroundCoureau, M., Meert, A., Berghmans, T., & Grigoriu, B. D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00137 · Cited by 48
Wölffer, M., Battke, F., Schulze, M., Feldhahn, M., Flatz, L., Martus, P., & Forschner, A. (2022) · Cancers · doi:10.3390/cancers14020302 · Cited by 38
“Other markers put forward in literature concern specific genes involved in immune system regulation [10].”
BackgroundPD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 37
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Ma, B., & Anandasabapathy, N. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.040 · Cited by 34
Immunotherapy in head and neck cancer: The great challenge of patient selection
Napolitano, M., Schipilliti, F. M., Trudu, L., & Bertolini, F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102829 · Cited by 24
Pharmacogenomics for immunotherapy and immune-related cardiotoxicity
Lal, J. C., Eng, C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa137 · Cited by 25
“Additionally, susceptibility loci in major histocompatibility complex (MHC) genes in patients of autoimmune disease linked to cardiac-related adverse have begun to show avenues of pharmacogenomic approaches in myocarditis and myopathies (50).”
BackgroundJiang, C. Y., Zhao, L., Green, M. D., Ravishankar, S., Towlerton, A. M. H., Scott, A. J., Raghavan, M., Cusick, M. F., Warren, E. H., & Ramnath, N. (2024) · Scientific Reports · doi:10.1038/s41598-023-48546-y · Cited by 23
“HLA genotypes of each patient were directly compared to each other and closely analyzed for similarities and the presence of HLA loci known to be associated with autoimmune endocrine disorders 40,41 .”
MethodCalabrese, L. H., Caporali, R. F., Blank, C. U., & Kirk, A. D. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102546 · Cited by 17
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 18
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
Hromić‐Jahjefendić, A., Lundstrom, K. H., Adilović, M., Aljabali, A. A. A., Tambuwala, M. M., Serrano‐Aroca, Á., & Uversky, V. N. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103508 · Cited by 15
Altena, R., Bajalica‐Lagercrantz, S., & Papakonstantinou, A. (2022) · Cancers · doi:10.3390/cancers14194665 · Cited by 15
“Polymorphisms shown to be related to autoimmune diseases have been suggested as potential predictive biomarkers of immune-related cardiotoxicity and other toxicities, but data supporting this hypothesis are currently lacking [67].”
BackgroundCutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors
Storgard, R., & Markova, A. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.03.034 · Cited by 14
Chau, C. Y. C., Shih, K. C., Chow, L. L. W., & Lee, V. H.-F. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00317-y · Cited by 9
Schmitt, C. R., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., González, J. V., Versluis, J. M., Compter, A., Harrer, T., Mijočević, H., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03498-0 · Cited by 8
“These autoreactive T cells could be pre-existing and perturbation of self-tolerance by ICI therapy could lead to reactivation, potentially due to genetic pre-disposition [43, 44].”
BackgroundAntonuzzo, A., Calabrò, F., Quaglino, P., Roila, F., Sebastiani, G. D., Spina, F., Pasqualetti, G., Cortinovis, D. L., Tagliaferri, E., Peri, A., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0035 · Cited by 8
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
Li, H., Sahu, K. K., & Maughan, B. L. (2022) · Cancers · doi:10.3390/cancers14102460 · Cited by 6
“Certain human leukocyte antigen (HLA) genes predispose people to developing autoimmune diseases such as myasthenia gravis, myocarditis, hepatitis, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome [84].”
BackgroundResultInfluentialUpdate on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management
Wang, D., Zhao, Y., Zeng, Y., Hu, L., & Xu, C. S. (2024) · Malignancy Spectrum · doi:10.1002/msp2.50 · Cited by 3
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis
Yu, X., Wu, J., & Su, C. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000909 · Cited by 2
“[27] extensively searched for susceptible loci and found that immune-related genes such as SP-C, AIRE, TERT and MUC5B might be contributing factors of CIP.”
BackgroundJiang, L., Ye, T., Cai, H., & He, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1784855 · Cited by 1
Zhukova, N. V., Орлова, Р. В., Malkova, A. M., Каледина, Е. А., Demchenkova, A., Percik, R., & Shoenfeld, Y. (2022) · Immunologic Research · doi:10.1007/s12026-022-09304-w · Cited by 1
“At the moment, there are no approved predictive biomarkers of immune adverse events, which makes timely diagnosis very difficult [11].”
Background
Metadata
- Authors
- Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Blank, Christian U.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 4
- Issue
- 4
- Pages
- e000472
- ISSN
- 2059-7029 (ISSN-L)
- PMC
- PMC6677983
- OpenAlex
- W2962814122
- Cited by
- 29
- References
- 213
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 3 · 2022: 8 · 2021: 3 · 2020: 8 · 2019: 2
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 643 d)
- Locations
- ESMO Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Pfizer
- Les Laboratories Pierre Fabre
- Ipsen
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, biomarkers, cancer immunotherapy, CTLA-4, PD-1, genetic susceptibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.